Dr. Shari Goldfarb, MD – New York, NY

Overview of Dr. Goldfarb

Dr. Shari Goldfarb is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from SUNY Upstate Medical University and has been in practice 13 years. Dr. Goldfarb accepts several types of health insurance, listed below. She is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 82 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 50 publications and over 500 citings.

Education & Training

• Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010

• NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007

• SUNY Upstate Medical UniversityClass of 2004

Certifications & Licensure

• FL State Medical License 2021 - Present

• NJ State Medical License 2020 - 2025

• NY State Medical License 2006 - 2024

• American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

• Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.

  McCann, K., Regan, M., Goldfarb, S., Traina, T., Vidula, N., Kaklamani, V.> ;NPJ Breast Cancer. 2024 Jan 19

• A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants.

  Kutluk H Oktay, Volkan Turan, Giuliano Bedoschi, Nadia Abdo, Heejung Bang, Shari Goldfarb> ;Cancer Medicine. 2023 Sep 1
• 2 citations

  Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment.

  Molly P Hogan, Joao V Horvat, Dara S Ross, Varadan Sevilimedu, Maxine S Jochelson, Laurie J Kirstein, Shari B Goldfarb, Christopher E Comstock, Janice S Sung> ;Breast Cancer Research and Treatment. 2023 Apr 1
• Join now to see all

Press Mentions

• Sermonix's Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 MutationMarch 6th, 2023

• Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023February 8th, 2023

• Breast Cancer Rates Among Younger Women Rise While Rates Among Older Women FallOctober 18th, 2022

• Join now to see all

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  BCBS Blue Card PPO
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  Empire BCBS HMO
  Empire BCBS PPO
  GHI PPO
  

  Great West PPO
  Humana ChoiceCare Network PPO
  MVP Healthcare PPO
  Oxford Health Freedom
  Oxford Health Liberty
  QualCare HMO
  QualCare PPO
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment